Forbion – Talk Bio

Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy

5 months ago talkbio0Tagged Citryll, Forbion, Inflammatory Disease Therapy, Johnson & Johnson Innovation, Neutrophil Extracellular Traps, Novartis, Series B, venture fund

Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion

Forbion Secures Over €2 Billion in Largest Fundraising to Date, Supporting 30 Biotechs

6 months ago talkbio0Tagged biotechs, Forbion, Fund III, Growth, venture, Ventures Fund VII

Forbion, venture capital, life sciences, fundraising, biotechs, Forbion Growth Opportunities Fund III, Forbion Ventures Fund VII

Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody

8 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune Diseases, Capital Management, Forbion, Funding, Navigator Medicines, Rheumatoid Arthritis, Series

Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion